

United Therapeutics Corp (UTHR) - Financial and Strategic SWOT Analysis Review

URL:	https://marketpublishers.com/r/UFEE7C3445EEN.html
Date:	June 6, 2017
Pages:	48
Price:	US\$ 125.00
ID:	UFEE7C3445EEN

United Therapeutics Corp (UTHR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

United Therapeutics Corp (UTC) develops and commercializes innovative pharmaceutical products for the treatment of cardiovascular disorders, particularly pulmonary arterial hypertension and infectious diseases. The company's products consist of prostacyclin analogues including Remodulin (treprostinil) injection and Tyvaso (treprostinil) inhalation solution; and Orenitram (treprostinil). Adcirca (tadalafil) is a phosphodiesterase type 5 (PDE-5) inhibitor and Unituxin (dinutuximab) is used for monoclonal antibody for oncologic applications are the other products. Its product candidates include monoclonal antibodies (mAbs), glycobiology antiviral agents and cell-based therapies. The company is also developing engineered lungs for transplantation in pre-clinical stage. The company manufactures its products in its facility in Silver Spring, Maryland. It operates in the US and markets its products across Europe, South America and Israel. UTC is headquartered in Maryland, the US.

United Therapeutics Corp Key Recent Developments

Apr 26,2017: United Therapeutics Reports First Quarter 2017 Financial Results

Mar 31,2017: SteadyMed Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent

Feb 22,2017: United Therapeutics Reports 2016 Fourth Quarter And Annual Financial Results

Oct 27,2016: United Therapeutics Reports Third Quarter 2016 Financial Results

Jul 28,2016: United Therapeutics Reports Second Quarter 2016 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Content

SECTION 1 - ABOUT THE COMPANY

United Therapeutics Corp - Key Facts

United Therapeutics Corp - Key Employees

United Therapeutics Corp - Key Employee Biographies

United Therapeutics Corp - Major Products and Services

United Therapeutics Corp - History

United Therapeutics Corp - Company Statement

United Therapeutics Corp - Locations And Subsidiaries

Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

United Therapeutics Corp - Business Description
United Therapeutics Corp - Corporate Strategy
United Therapeutics Corp - SWOT Analysis
SWOT Analysis - Overview
United Therapeutics Corp - Strengths
United Therapeutics Corp - Weaknesses
United Therapeutics Corp - Opportunities
United Therapeutics Corp - Threats
United Therapeutics Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

United Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
United Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
United Therapeutics Corp, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Apr 26, 2017: United Therapeutics Reports First Quarter 2017 Financial Results
Mar 31, 2017: SteadyMed Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent
Feb 22, 2017: United Therapeutics Reports 2016 Fourth Quarter And Annual Financial Results
Oct 27, 2016: United Therapeutics Reports Third Quarter 2016 Financial Results
Jul 28, 2016: United Therapeutics Reports Second Quarter 2016 Financial Results
Apr 28, 2016: United Therapeutics Reports First Quarter 2016 Financial Results
Apr 28, 2016: United Therapeutics Announces Executive Leadership Changes
Feb 25, 2016: United Therapeutics Corporation Reports 2015 Fourth Quarter And Annual Financial Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

United Therapeutics Corp, Key Facts
United Therapeutics Corp, Key Employees
United Therapeutics Corp, Key Employee Biographies

United Therapeutics Corp, Major Products and Services
United Therapeutics Corp, History
United Therapeutics Corp, Other Locations
United Therapeutics Corp, Subsidiaries
United Therapeutics Corp, Key Competitors
United Therapeutics Corp, Ratios based on current share price
United Therapeutics Corp, Annual Ratios
United Therapeutics Corp, Annual Ratios (Cont.1)
United Therapeutics Corp, Annual Ratios (Cont.2)
United Therapeutics Corp, Interim Ratios
United Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
United Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
United Therapeutics Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

United Therapeutics Corp, Performance Chart (2012 - 2016)
United Therapeutics Corp, Ratio Charts
United Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
United Therapeutics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Teva Pharmaceuticals USA Inc
GlaxoSmithKline Plc
Gilead Sciences Inc
CoTherix Inc
Actelion Ltd

I would like to order:

Product name: United Therapeutics Corp (UTHR) - Financial and Strategic SWOT Analysis Review
Product link: <https://marketpublishers.com/r/UFEE7C3445EEN.html>
Product ID: UFEE7C3445EEN
Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/UFEE7C3445EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**